USPTO serial 99457431
OATH
Reviewed by CopyMark Law Group
Status 653
- Filing date
- Status date
- Registration date
- —
- Examiner
- SAUNDERS, ANDREA DAWN
- Law office
- TMO LAW OFFICE 137
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with OATH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
San Francisco, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Isaac M. Fine
Isaac M. Fine KPPB LLP180 E. Ocean Blvd., Suite 1030Long Beach, CA 90802United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for alleviating side effects of cancer treatments; Pharmaceutical preparations for alleviating side effects of chemotherapy; Pharmaceutical preparations for alleviating side effects of radiation therapy; Pharmaceutical preparations for alleviating side effects of targeted cancer treatments; Pharmaceutical preparations for alleviating side effects of targeted cancer treatments, namely, tyrosine kinase inhibitors; Pharmaceutical preparations for alleviating side effects of immunotherapy treatments; Pharmaceutical preparations for alleviating gastrointestinal distress, mucocitis, nausea, vomiting and diarrhea; Pharmaceutical preparations for stimulating appetite; Pharmaceutical preparations for preventing weight loss; Pharmaceutical preparations for protecting bone marrow and the production of bone marrow; Pharmaceutical preparations for protecting stem cells and stimulating the production of stem cells; Pharmaceutical preparations for increasing resiliency of stem cells, increasing the number of stem cells, and preventing the reduction of stem cell populations; Pharmaceutical preparations for protecting blood cells, alleviating anemia, neutropenia, thrombocytopenia, and alleviating low blood counts; Pharmaceutical preparations for alleviating dose limiting side effects of cancer treatments, chemotherapy, radiation therapy, targeted cancer treatments and immunotherapy treatments; Pharmaceutical preparations for the prevention and treatment of side effects of cancer treatments; Pharmaceutical preparations for the prevention and treatment of side effects of chemotherapy; Pharmaceutical preparations for the prevention and treatment of side effects of radiation therapy; Pharmaceutical preparations for the prevention and treatment of side effects of targeted cancer treatments; Pharmaceutical preparations for the prevention and treatment of side effects of targeted cancer treatments, namely, tyrosine kinase inhibitors; Pharmaceutical preparations for the prevention and treatment of side effects of immunotherapy treatments; Pharmaceutical preparations for the prevention and treatment of gastrointestinal distress, mucocitis, nausea, vomiting and diarrhea; Pharmaceutical preparations for the prevention and treatment of loss of appetite; Pharmaceutical preparations for the prevention and treatment of weight loss; Pharmaceutical preparations for the treatment and prevention of bone marrow damage; Pharmaceutical preparations for the treatment and prevention of stem cell damage and reduction of stem cell populations; Pharmaceutical preparations for the treatment and prevention of blood cell damage, anemia, and low blood count; Pharmaceutical preparations for the treatment and prevention of dose limiting side effects of cancer treatments, chemotherapy, radiation therapy, targeted cancer treatments and immunotherapy treatments; Pharmaceutical preparations for the treatment and prevention of side effects of cancer treatments, chemotherapy, radiation therapy, targeted cancer treatments and immunotherapy treatments, namely, reduced fertility; Pharmaceutical preparations for supporting stem cell health and production; Pharmaceutical preparations for supporting stem cell health and production, namely for stimulating uterine, bone marrow and gastrointestinal track stem cell production; Pharmaceutical preparations for the treatment of radiation exposure; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of inflammatory bowel disease, ulcerative colitis and other inflammatory bowel disorders; Pharmaceutical preparations for the enhancement of chemotherapy; Pharmaceutical preparations for the enhancement of immunotherapy; Fertility enhancement preparations; all of the foregoing requiring a prescription | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 26, 2026 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jul 26, 2026 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jul 26, 2026 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jul 22, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 22, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 22, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 22, 2026 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Apr 22, 2026 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jan 22, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 22, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 22, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 22, 2026 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jan 22, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 21, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 12, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 12, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 12, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 22, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 22, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 22, 2025 | NWAP | NEW APPLICATION ENTERED | — |